Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine (Q46691027)

24 December 2017

title

Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine (English)

1 reference

24 December 2017

author name string

Lee BL

1 reference

24 December 2017

Täuber MG

1 reference

24 December 2017

Sadler B

1 reference

24 December 2017

Goldstein D

1 reference

24 December 2017

Chambers HF

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 January 1996

1 reference

24 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

24 December 2017

volume

1 reference

24 December 2017

issue

1 reference

24 December 2017

page(s)

14-21

1 reference

24 December 2017

Interactions and Toxicities of Drugs Used in Patients with AIDS

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

High-performance liquid chromatographic assay for the measurement of atovaquone in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Atovaquone - a novel broad-spectrum anti-infective drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

Reduction of 3'-azido-3'-deoxythymidine to 3'-amino-3'-deoxythymidine in human liver microsomes and its relationship to cytochrome P450

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990019-3

10.1016/S0009-9236(96)90019-3

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017